334 related articles for article (PubMed ID: 31325646)
1. Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients.
Timmins HC; Li T; Kiernan MC; Horvath LG; Goldstein D; Park SB
J Pain; 2020; 21(1-2):44-58. PubMed ID: 31325646
[TBL] [Abstract][Full Text] [Related]
2. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity.
Park SB; Alberti P; Kolb NA; Gewandter JS; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S13-S25. PubMed ID: 31647154
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics.
Bennedsgaard K; Ventzel L; Andersen NT; Themistocleous AC; Bennett DL; Jensen TS; Tankisi H; Finnerup NB
J Peripher Nerv Syst; 2020 Dec; 25(4):377-387. PubMed ID: 32902058
[TBL] [Abstract][Full Text] [Related]
4. Small-fiber neuropathy: Expanding the clinical pain universe.
Sopacua M; Hoeijmakers JGJ; Merkies ISJ; Lauria G; Waxman SG; Faber CG
J Peripher Nerv Syst; 2019 Mar; 24(1):19-33. PubMed ID: 30569495
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Patients With and Without Painful Peripheral Neuropathy After Receiving Neurotoxic Chemotherapy: Traditional Quantitative Sensory Testing vs C-Fiber and Aδ-Fiber Selective Diode Laser Stimulation.
Nemenov MI; Alaverdyan H; Burk C; Roles K; Frey K; Yan Y; Kazinets G; Haroutounian S
J Pain; 2022 May; 23(5):796-809. PubMed ID: 34896646
[TBL] [Abstract][Full Text] [Related]
6. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study.
Velasco R; Navarro X; Gil-Gil M; Herrando-Grabulosa M; Calls A; Bruna J
J Pain Symptom Manage; 2017 Dec; 54(6):815-825. PubMed ID: 28797868
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced peripheral neuropathy: where are we now?
Colvin LA
Pain; 2019 May; 160 Suppl 1(Suppl 1):S1-S10. PubMed ID: 31008843
[TBL] [Abstract][Full Text] [Related]
8. An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models.
Bouchenaki H; Danigo A; Sturtz F; Hajj R; Magy L; Demiot C
Fundam Clin Pharmacol; 2021 Jun; 35(3):506-523. PubMed ID: 33107619
[TBL] [Abstract][Full Text] [Related]
9. Current Diagnosis and Treatment of Painful Small Fiber Neuropathy.
Farhad K
Curr Neurol Neurosci Rep; 2019 Nov; 19(12):103. PubMed ID: 31773305
[TBL] [Abstract][Full Text] [Related]
10. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy.
Saad M; Psimaras D; Tafani C; Sallansonnet-Froment M; Calvet JH; Vilier A; Tigaud JM; Bompaire F; Lebouteux M; de Greslan T; Ceccaldi B; Poirier JM; Ferrand FR; Le Moulec S; Huillard O; Goldwasser F; Taillia H; Maisonobe T; Ricard D
J Neurooncol; 2016 Apr; 127(2):373-80. PubMed ID: 26749101
[TBL] [Abstract][Full Text] [Related]
11. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA
Cancer Treat Rev; 2016 Nov; 50():118-128. PubMed ID: 27664395
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Park SB; Goldstein D; Krishnan AV; Lin CS; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC
CA Cancer J Clin; 2013; 63(6):419-37. PubMed ID: 24590861
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
[TBL] [Abstract][Full Text] [Related]
14. Role of Mitochondrial Mechanism in Chemotherapy-Induced Peripheral Neuropathy.
Waseem M; Kaushik P; Tabassum H; Parvez S
Curr Drug Metab; 2018; 19(1):47-54. PubMed ID: 29219049
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal follow-up of biopsy-proven small fiber neuropathy.
MacDonald S; Sharma TL; Li J; Polston D; Li Y
Muscle Nerve; 2019 Oct; 60(4):376-381. PubMed ID: 31348533
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity.
Sałat K
Pharmacol Rep; 2020 Jun; 72(3):508-527. PubMed ID: 32347537
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
18. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.
McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB
J Cancer Surviv; 2019 Aug; 13(4):495-502. PubMed ID: 31172429
[TBL] [Abstract][Full Text] [Related]
19. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review.
Haroutounian S; Todorovic MS; Leinders M; Campagnolo M; Gewandter JS; Dworkin RH; Freeman R
Muscle Nerve; 2021 Feb; 63(2):170-177. PubMed ID: 32989823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
